通络胶囊治疗糖尿病肾病慢性肾衰竭的临床研究

Clinical Study on Effect of Tongluo Capsule in Treating Diabetic Nephropathy Caused Chronic Renal Failure

目的观察通络胶囊对糖尿病肾病 (diabeticnephropathy ,DN)合并慢性肾衰竭 (chronicrenalfailure ,CRF)患者的治疗作用 ,并初步探讨其作用机理。方法 97例糖尿病肾病慢性肾衰竭患者 ,随机分为通络胶囊治疗组 (简称中药组 ,5 0例 )和西药治疗组 (简称西药组 ,4 7例 )。治疗 6个月后 ,观察通络胶囊对患者治疗前后 2 4h尿蛋白、肾功能〔血肌酐 (Cr)、尿素氮 (BUN)〕、血脂〔胆固醇 (TC) ,甘油三酯 (TG) ,高密度脂蛋白胆固醇 (HDL C)、低密度脂蛋白胆固醇 (LDL C)〕及血清转化生长因子 (TGF β1)的变化。结果治疗后两组患者 2 4h尿蛋白 ,Cr ,BUN及血清TGF β1水平明显降低 ,与治疗前比较 ,差异有显著性 (P <0 0 1) ,而且中药通络胶囊对Cr,BUN及血清TGF β1水平的治疗效果优于西药 (P <0 0 1) ,并且还可以降低TC ,TG及LDL C水平 (P <0 0 5 ,P <0 0 1)。结论通络胶囊可能是通过降低血脂及血清TGF

Objective To observe the therapeutic effect of Tongluo capsule (TLC) in treating diabetic nephropathy (DN) complicated chronic renal failure (CRF), and to explore its mechanism preliminarily. Methods Ninety seven patients with DN CRF were randomly divided into the TCM group (n=50) and the WM group (n=47) to observe the changes of urinary protein per 24 hrs (UP/24h), renal function, creatinine (Cr), blood urea nitrogen (BUN), blood lipids (TG, TC, HDL C, LDL C) and serum transforming growth factor β 1 (TGF β 1) before and after treatment. Results After 6 months of treatment, levels of UP/24h, Cr, BUN and TGF β 1 significantly lowered in both groups (P<0 01), and a better effect was showed in the TCM group in aspects of lowering Cr, BUN and TGF β 1 (P<0 01). Besides, TLC also showed effect in lowering the serum lipid parameters (P<0 05 or P<0 01). ConclusionEffect of TLC in treating DN CRF might be through lowering the levels of blood lipids and serum TGF β 1.